Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation: 2021-2025

Historic Share-based Compensation for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $10.1 million.

  • Kiniksa Pharmaceuticals International's Share-based Compensation rose 29.62% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.1 million, marking a year-over-year increase of 16.24%. This contributed to the annual value of $30.7 million for FY2024, which is 13.05% up from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Share-based Compensation stood at $10.1 million, which was up 14.29% from $8.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Share-based Compensation high stood at $10.1 million for Q3 2025, and its period low was $5.7 million during Q2 2021.
  • Its 3-year average for Share-based Compensation is $7.7 million, with a median of $7.7 million in 2025.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Share-based Compensation declined by 15.37% in 2022 and then rose by 29.62% in 2025.
  • Kiniksa Pharmaceuticals International's Share-based Compensation (Quarterly) stood at $6.1 million in 2021, then climbed by 3.93% to $6.4 million in 2022, then climbed by 21.99% to $7.8 million in 2023, then climbed by 6.75% to $8.3 million in 2024, then rose by 29.62% to $10.1 million in 2025.
  • Its last three reported values are $10.1 million in Q3 2025, $8.9 million for Q2 2025, and $7.7 million during Q1 2025.